A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients

NCT00518323 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

201

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Paliperidone ER
DRUG: Placebo
DRUG: Paliperidone ER
DRUG: Paliperidone ER

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.